Large-cell neuroendocrine carcinoma of the lung

Cancer Control

Volumn 13, Issue 4, 2006, Pages 270-275

  Fernandez, Felix G ^a   Battafarano, Richard J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; OCTREOTIDE;

CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; HUMAN; INCIDENCE; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG; LUNG CANCER; NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW;

EID: 33750172601     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300404     Document Type: Review

References (33)

1. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972;64:413-421.
2. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma: an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529-553.
3. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22: 934-944.
4. Dresler CM, Ritter JH, Patterson GA, et al. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 1997;63:180-185.
5. Travis WD, Travis WD, Colby TV, et al. Histological typing of lung and pleural tumors. In: International Histological Classification of Tumors. 3rd ed. Springer Verlag, Berlin; 1999.
6. Jiang SX, Kameya T, Shoji M, et al. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol. 1998;22:526-537.
7. Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg. 2002;124:285-292.
8. Iyoda A, Hiroshima K, Toyozaki T, et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001;91:1992-2000.
9. Paci M, Cavazza A, Annessi V, et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg. 2004;77:1163-1167.
10. Battafarano RJ, Fernandez FG, Ritter J, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130:166-172.
11. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70-76.
12. Doddoli C, Barlesi F, Chetaille B, et al. Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially treatable with surgery. Ann Thorac Surg. 2004;77:1168-1172.
13. Garcia-Yuste M, Matilla JM, Alvarez-Gago T, et al. Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Ann Thorac Surg. 2000;70:258-263.
14. Zacharias J, Nicholson AG, Ladas GP, et al. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg. 2003;75:348-352.
15. Marchevsky AM, Gal AA, Shah S, et al. Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol. 2001;116:466-472.
16. Wick MR, Berg LC, Hertz MI. Large cell carcinoma of the lung with neuroendocrine differentiation: a comparison with large cell "undifferentiated" pulmonary tumors. Am J Clin Pathol. 1992;97:796-805.
17. Ab'Saber AM, Massoni Neto LM, Bianchi CP, et al. Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas. Ann Thorac Surg. 2004;77:1883-1890.
18. Iyoda A, Hiroshima K, Moriya Y, et al. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg. 2004;77:1891-1895.
19. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg. 1996;62:798-810.
20. Przygodzki RM, Finkelstein SD, Langer JC, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol. 1996;148:1531-1541.
21. Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3, and 5 in biopsies and specimens of human lung tumours. Virchows Arch. 2001;439:787-797.
22. Kwekkeboom DJ, Kho GS, Lamberts SW, et al. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med. 1994;21:1106-1113.
23. Musi M, Carbone RG, Bertocchi C, et al. Bronchial carcinoid tumours: a study on clinicopathologic features and role of octreotide scintigraphy. Lung Cancer. 1998;22:97-102.
24. Filosso PL, Ruffini E, Oliaro A, et al. Long-term survival of atypical bronchial carcinoid with liver metastases, treated with octreotide. Eur J Cardiothoracic Surg. 2002;21:913-917.
25. Battafarano RJ, Lewis JS, Ritter J, et al. Gene expression profiling distinguishes large cell lung cancer with disparate clinical outcomes. Presented at the 11th World Conference on Lung Cancer; July 3-6, 2005; Barcelona, Spain. Abstract 1872.
26. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002;123:280-287.
27. Cooper WA, Thourani VH, Gal AA, et al. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest. 2001;119:14-18.
28. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation on non-small cell lung cancer: the LCSG experience. Chest. 1994;106(6 suppl):367S-371S.
29. Travis WD, Gal AA, Colby TV, et al. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol. 1998;29:272-279.
30. Hage R, Seldenrijk K, de Bruin P, et al. Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardiothorac Surg. 2003;23:457-460.
31. Iyoda A, Hiroshima K, Toyozaki T, et al. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer. 2001;92:1108-1112.
32. Lai SL, Goldstein LJ, Gottesman MM, et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst. 1989;81:1144-1150.
33. O'Byrne KJ, Schally AV, Thomas A, et al. Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy. 2001;47:78-108.